Post-earnings recap
Reported
Thu, Aug 7, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Amicus Therapeutics is still facing challenges, particularly in terms of revenue generation. The stock's decline of 5.63% reflects investor concerns about the company's ability to meet future expectations. The slight EPS beat may not have been enough to offset worries about overall performance and market conditions.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | +7.17% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions impacting performance. They remain focused on their long-term vision.
Management noted ongoing challenges in achieving revenue targets.
They emphasized a focus on long-term strategic goals despite short-term setbacks.